Please login to the form below

Not currently logged in
Email:
Password:

Gilead works with Indian generic firms to improve HIV drug access

Collaboration with Mylan, Ranbaxy and Strides aims to reduce cost of emtricitabine

Gilead Sciences

Gilead have agreed to collaborate with generic firms Mylan, Ranbaxy and Strides to reduce manufacturing costs, accelerate access and improve availability of Gilead's HIV medicine emtricitabine (FTC) in developing countries.

This agreement includes single tablet regimens containing emtricitabine and fixed-dose combinations of emtricitabine co-formulated with other Gilead HIV medicines.

Emtricitabine, which is marketed by Gilead under the brand name Emtriva, is recommended by World Health Organization (WHO), along with well tenofovir disoproxil fumarate (TDF), as the preferred components of first and second line HIV therapy.

The agreement will also see the India-based generic companies take over manufacturing of emtricitabine from Gilead, as well as fund process improvements to reduce manufacturing costs.

Within developing countries it is thought that there are around 3m people living with HIV/AIDS who are receiving medicine, and 2.7m of those receive a TDF-containing regime, a medicine originally developed by Gilead and that is now licensed to generic manufacturers.

However, it is estimated that around 7m people are still in need of treatment and are waiting for access to medicines, according to a special report from Médecins Sans Frontières.

By reducing costs and bringing manufacturing closer to developing nations, it is hoped that vital HIV/AIDS drugs will reach a greater number of those in need of treatment.

A total of thirteen Indian generic companies now have licensed Gilead HIV medicines through non-exclusive generic licensing agreements established with generic manufacturers.

Mylan CEO Heather Bresch commented that she was “delighted to be collaborating with Gilead” in an attempt to enable greater access to affordable medicine for HIV in developing countries.

6th August 2012

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Excel Communications

Excel Communications is a world class training and development company facilitating tailored, in-house learning events including coaching, workshops and development...

Latest intelligence

Leveraging HCP Transparency Insights to Drive Future Customer Investments
EFPIA’s disclosure requirements present an opportunity to assess strategy and effectiveness...
How did pharma use Twitter at #ASCO16?
Each year, ASCO’s Annual Meeting brings together 30,000 oncology professionals from around the world, here we explore the #ASCO16 hashtag and how pharma utilised the channel during this year's event....
WHITE PAPER: How to engage with HCPs more effectively
Shrinking budgets and limitations on the time HCPs can spend with sales reps is making traditional engagement methods more and more ineffective. So, in order to reach the unreachable, pharma...

Infographics